Drugs / JNJ-70218902
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06788509 | Dec 2024 → Jan 2028 expected | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, castration-resistant prostate carcinoma, myelodysplastic syndrome | Janssen Research & Development, LLC | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT04397276 | Jul 2020 → Sep 2025 | neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-70218902 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06788509 ↗ |
| Modality | Other / unclassified | “JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors” NCT04397276 ↗ |
| Route | Oral | “will continue to receive JNJ-70218902 orally.” NCT06788509 ↗ |